Skip to main content
Create Account
About PLI PLUS
Help
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- Treatises
Forms
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Developments in Pharmaceutical and Biotech Patent Law 2015
Chair(s):
David K. Barr, Daniel L. Reisner
Practice Area:
Intellectual Property
Published:
Oct 2015
ISBN:
9781402425271
PLI Item #:
136819
CHB Spine #:
G1240
This version is not current.
Click here for the most recent version.
Terms & Connectors
Natural Language
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Related Items
Select All
Front Matter
Faculty Bios
Table of Contents
Chapter 1. Indefiniteness and Claim Construction: Nautilus and Teva
Chapter 2. Chapter 5 Patentability excerpt: Indefiniteness and the Requirement to Claim the Invention, Reprinted from the PLI Legal Treatise, Pharmaceutical and Biotech Patent Law (Order #15140)
Chapter 3. Chapter 9 Claim Construction, Reprinted from the PLI Legal Treatise, Pharmaceutical and Biotech Patent Law (Order #15140)
Chapter 4. Chapter 14 Biologic and Biosimilar Drug Products, Prepublication Revision, PLI Legal Treatise, Pharmaceutical and Biotech Patent Law
Chapter 5. Major Judicial Decisions Impacting Pharmaceutical and Biotech Patents (July 10, 2015)
Chapter 6. Leveraging AIA’s Tools for Your Competitive Advantage: Strategic Implications of Post-Grant Challenges for Life Sciences Companies
Chapter 7. Section 101: Patentable Subject Matter in the Aftermath of Myriad and Mayo
Chapter 8. Subject Matter Conflicts and Advance Waivers in Patent Prosecution, Counseling and Litigation
Index
About Us
